Shares of Moderna dropped 2.78% to $152.89 at 15:10 EST on Friday, after two consecutive sessions in a row of gains. The Nasdaq Stock Market is jumping 0.4% to $12,426.90, following yesterday’s upward trend, on what as yet seems, a somewhat positive trend exchanging session today.

Moderna’s last close was $157.26, 16.75% below its 52-week high of $178.50.

News about Moderna today

Moderna expects to provide up to 125 mln covid-19 vaccine doses globally in q1. According to today’s article on Business Insider, “Moderna Inc. said Thursday that it expects to have between 100 million and 125 million doses of its potential COVID-19 vaccine available globally in the first quarter of 2021, with 85 million-100 million of those available in the U.S”

Moderna to provide israel health ministry with additional 4 million doses of its covid-19 vaccine candidate. According to today’s article on MarketWatch, “Moderna Inc. said Friday it is amending its supply agreement with the Israeli health ministry and will provide an additional 4 million doses of its experimental COVID-19 vaccine mRNA-1273”

Moderna’s Sales

Moderna’s sales growth is 1428.1% for the present quarter and 12348.6% for the next. The company’s growth estimates for the present quarter is a negative 48.6% and positive 528.6% for the next.

Moderna’s Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna’s Stock Top and Bottom Yearly Value

Moderna’s stock is valued at $152.89 at 15:10 EST, way below its 52-week high of $178.50 and way higher than its 52-week low of $17.68.

Moderna’s Moving Average

Moderna’s worth is way above its 50-day moving average of $88.87 and way higher than its 200-day moving average of $73.28.

Previous days news about Moderna

Moderna set to file for us, EU clearance for its coronavirus vaccine. According to ForexLive on Mon Nov 30, “Moderna reaffirms that its vaccine is 94.1% effective in primary analysis
– Vaccine was 94.1% effective in analysis of Phase 3 study, after 196 virus cases
– Vaccine was 100% effective against strict virus cases in trial
Another Monday, another dose of vaccine optimism to hit the market.”

Moderna to ask FDA to authorize vaccine. According to The Wall Street Journal on Mon Nov 30, “Moderna will ask U.S. and European health regulators today to authorize use of its Covid-19 vaccine after it was previewn to be 94.1% effective in a full analysis of a pivotal study, keeping it on track to go into use in the U.S”

According to Bloomberg Quint on Mon Nov 30, “Moderna Plans to Seek U.S., EU Clearance for Covid Vaccine.”

Moderna to file EUA for coronavirus vaccine candidate, which previewed 94.1% efficacy. According to MarketWatch on Mon Nov 30, “Moderna Inc. said Monday that it will file for emergency use authorization from the Food and Drug Administration for its coronavirus vaccine candidate, mRNA-1273”

According to MarketWatch on Mon Nov 30, “Moderna shares soar 11% on filing for emergency-use authorization for vaccine.”

According to Bloomberg Quint on Mon Nov 30, “Moderna Seeks Approval; WHO Spotlights Risks: Virus Update.”

Moderna mania draws bitcoin comparisons while shorts bleed. According to Bloomberg Quint on Tue Dec 1, “Moderna Mania Draws Comparisons to Bitcoin While Shorts Bleed.”

According to Bloomberg Quint on Wed Dec 2, “Moderna Falls After Merck Sells Stake in the Vaccine Maker.”

According to Bloomberg Quint on Wed Dec 2, “Astra Data, Novavax Delay Spur Moderna Vaccine Demand, CEO Says.”


Please enter your comment!
Please enter your name here